Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC) Meeting Abstract
| Authors: | DeMichele, A.; Harding, J. J.; Telli, M. L.; Munster, P. N.; McKay, R.; Iliopoulos, O.; Orford, K. W.; Bennett, M. K.; Mier, J. W.; Owonikoko, T. K.; Patel, M. R.; Carvajal, R. D.; Meric-Bernstam, F.; Infante, J. R. |
| Abstract Title: | Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 45s |
| Language: | English |
| ACCESSION: | WOS:000404665401133 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.1011 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1011 -- Source: Wos |
